Results 101 to 110 of about 23,087 (229)

Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients

, 2012
Andrew J Yee, Noopur S RajeDivision of Hematology-Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USAAbstract: Bone loss is a common side effect of cancer treatments, especially antihormonal treatments used in the treatment of breast ...
Raje NS, Yee AJ
core  

Exceptional Locoregional Pathological Response in Metastatic Triple‐Negative Breast Cancer Treated With Palliative Platinum‐Based Chemotherapy

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT Locoregional pathological complete response with concurrent radiologic metabolic remission following palliative gemcitabine–carboplatin chemotherapy in young, low‐grade metastatic triple‐negative breast cancer patient suggests potential chemosensitivity in select advanced cases, warranting further clinical investigation.
Shristi Gupta, Abhisek Jha, Asmita Rayamajhi, Aron Neupane, Kshitiz Parajuli, Manash Jha   +5 more
wiley   +1 more source

Case report: A case of ITP-like thrombocytopenia induced by denosumab

Frontiers in Pharmacology
Denosumab has been widely utilized in the management of osteoporosis; however, thrombocytopenia as an adverse reaction associated with denosumab has been infrequently reported, and its underlying mechanism is not yet fully understood.
Shijing Chen, Xiahong Lin
doaj   +1 more source

High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis

, 2016
Koji Ishikawa,1 Takashi Nagai,1 Keizo Sakamoto,1 Kenji Ohara,2 Takeshi Eguro,1,2 Hiroshi Ito,1 Yoichi Toyoshima,1 Akatsuki Kokaze,3 Tomoaki Toyone,1 Katsunori Inagaki1 1Department of Orthopaedic Surgery, Showa University School of Medicine, Tokyo ...
Ohara K, Inagaki K, Eguro T, Kokaze A, Nagai T, Sakamoto K, Ito H, Ishikawa K, Toyoshima Y, Toyone T   +9 more
core  

Nitrogen‐Based Bisphosphonate Use and Risk of Cancer in Women Aged 50 Years and Older: A National Data Linkage Study

International Journal of Cancer, Volume 159, Issue 7, Page 1669-1685, 1 October 2026.
Bisphosphonates are widely used to treat osteoporosis and to manage bone metastases in patients with breast cancer. Nitrogen‐based bisphosphonates may also broadly reduce cancer risk, but evidence remains inconsistent. This large population‐based data linkage study in women aged > 50 years found that, compared to no use of osteoporosis medicines ...
Karen M. Tuesley, Fiona Caristo, Katrina Spilsbury, Sallie‐Anne Pearson, Peter Donovan, Michael D. Coory, Christopher B. Steer, Susan J. Jordan   +7 more
wiley   +1 more source

Osteogenesis Imperfecta: A Review of Denosumab Research

, 2020
This article reviews the emerging literature on the efficacy of denosumab as a treatment for patients with Osteogenesis Imperfecta (OI). Denosumab improves bone density in adults with osteoporosis.
Kopplin, Echo L
core   +1 more source

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain

, 2015
Josep Darbà,1 Lisette Kaskens,2 Francesc Sorio Vilela,3 Mickael Lothgren4 1Department of Economics, Universitat de Barcelona, 2BCN Health Economics and Outcomes Research SL, 3Amgen SA, Barcelona, Spain; 4Amgen (Europe) GmbH, Zug, Switzerland ...
Darbà J, Lothgren M, Kaskens L, Sorio Vilela F   +3 more
core  

Osteomyelitis: Epidemiology, Classification, Pathophysiology, Clinical Features, Diagnosis, and Management

MedComm, Volume 7, Issue 10, October 2026.
The immunosuppressive in OM Staphylococcus aureus employs multiple physical barriers to evade host immunity during skeletal infection, including biofilm formation on implant surfaces and necrotic bone tissues, invasion into the osteocyte lacuno‐canalicular network (OLCN), intracellular persistence within osteoblasts, osteoclasts, and osteocytes, and ...
Qingqiang Lei, Liangbin Lin, Peidong Pu, Jie Chen, Xianchao Su, Shubao Liu, Yanli Tong, Hui Yu   +7 more
wiley   +1 more source

DENOSUMAB TÜRKİYE VERİLERİ: KRONİK BÖBREK HASTALIĞI’NIN DENOSUMAB SONLANIM NOKTALARINA ETKİSİ; TÜRK ONKOLOJİ GRUBU(TOG) ÇALIŞMAS

, 2023
Amaç: Denosumab, kemik remodellingini düzenleyen önemli bir ligand olan NFkB ligandının (RANKL) reseptör aktivatörünü spesifik olarak bağlar ve inaktive eder.
Semiz, Hüseyin Salih, Alan, Özkan, Aksoy, Sercan, Yeşil Çınkır, Havva, İlhan, Yusuf, Yıldırım, Nilgün, Yavuzşen, Tuğba, Ak, Naziye, Özçelik, Melike, Turhal, Serdar, Yıldırım, Hasan Çağrı, Düzköprü, Yakup, Karaboyun, Kubilay, Türkmen Bekmez, Esra, Ellez, Halil İbrahim, Imamoğlu, Gökçen Inanç, Kuş, Fatih, Bayram, Ertuğrul, Sakalar, Teoman, Erdoğan, Atike Pınar, Ekinci, Ferhat, Karakurt Eryılmaz, Melek, Karataş, Fatih   +22 more
core   +1 more source

Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience

Therapeutic Advances in Urology, 2017
Osteoprotective therapies have become an essential component in the management of advanced prostate cancer (PC) patients as bone metastases (BMs) have a major impact on morbidity and mortality.
Miriam Hegemann, Jens Bedke, Arnulf Stenzl, Tilman Todenhöfer   +3 more
doaj   +1 more source